제넥신 로고

After graduating from Yonsei University with a degree in biochemistry, Dr. Sung received his PhD degree in molecular biology from the University of Minnesota in the United States and worked as a researcher at the Department of Pathology at Harvard Medical School. In July 1989, he began his professorship at the Department of Life Science in Pohang University of Science and Technology and continued in this position. In June 1999, he founded Genexine and subsequently grew the company to a worth of over 1 trillion won. To develop novel drugs with “Open Innovation” and “Together Culture” as the foundations for success, we motivated professionals to develop novel drugs using Genexine’s outstanding proprietary technologies, joint development efforts with a fusion of technologies from major domestic and foreign pharmaceutical companies, and establishment of joint ventures in different parts of the world.

President Hee Jeong, Ji leads the research and development (R&D) organization. Since 2018, she has been working as the head of the research institute of Genexine and is in charge of the development of protein/gene production technology. President Hee jeong Ji graduated from the Department of zBiochemistry at Yonsei University, received a Ph.D. in Biochemistry from Purddue University, and continued her research activities as a post-doctoral researcher in the Department of Biology at the University. Since then, in order to realize the dream of biopharmaceutical research and development, she was able to accumulate experience in global biopharmaceutical research and development and permitting, such as vaccine development and growth hormone, while working at the LG Chemical Bio Lab and Development Department. Since 2013, she served as the head of the Green Cross Development Division, where he participated in the development of rare medicines such as blood products, vaccines and hunterases, including immunoglobulins. Currently, she is in charge of CMC development of long-acting interleukin 7 and DNA therapy vaccine preparations for the development of immunoneoplastics, which is the main research area of Genexine.

President Dr. Jung Won Woo leads the Protein Manufacturing Technology Research Institute, Business and Clinical Development. She is working in charge of all clinical development and global license deals. Dr. Woo received her BS and MS degrees in pharmacy from Seoul National University and her PhD degree in microbiology from Cornell University. After completing her post-doc fellowship at Harvard Medical School, she started working as a senior researcher at Samsung Bio Research Institute and researcher at Convergent Research Consortium for Immunologic Disease (CRCID) in Seoul St. Mary’s Hospital. She works closely with various internal and external affiliates to support Genexine’s vision of becoming an innovative biotechnology company through the development of first-in-the-world novel drugs. Based on her extensive experience, she is also involved in developing the strategic direction of the company from a long-term perspective of global partnerships, commercialization, and clinical applications.

Vice President You Suk Suh leads the DNA Manufacturing Technology Institute. Dr. Suh joined Genexine in 2006 and held multiple leadership positions over the years in Genexine, including Head of Bio Efficacy Center before taking his current position. Also, Dr. Suh has been served as Head of DNA vaccine research institute and head QA. Dr. Suh received his Ph.D. degree from POSTECH (Korea) and postdoctoral training at German Primate Center (DPZ)(Germany). He conducted gene therapy vaccine research at Alexander-von-Humboldt foundation in Germany and HIV DNA vaccine research at POSTECH prior to joining Genexine.

After his retirement from Catholic Medical Center, Dr. Jong Sup Park joined Genexine in March 2019 to serve as the company’s chief medical officer (CMO). Dr. Park had previously served as a practicing physician in the gynecology department at Seoul St. Mary’s Hospital and as a research professor at Johns Hopkins Medical School. Dr. Park has been a respected gynecologic oncologist and is recognized as a renowned biomedical researcher of HPV and cervical cancer in South Korea for the past three decades. He also established the Asia-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) to educate clinicians and health workers living in the Asia-Pacific region. Based on his wealth of experience, Dr. Park oversees the clinical progress of a therapeutic DNA vaccine for cervical cancer at Genexine.

As vice president and CFO, Sung June Hong is in charge of financial, legal, SCM, investor communication(IR), and management support matters to establish advanced management systems and play the role of a business partner to the businesses. He has earned his bachelor's and master's degrees in business administration from Yonsei University and also received master's degree in laws from Vanderbilt Law School. As a financial and legal expert qualified in South Korea and the United States, he has been managing strategic, legal, and financial aspects of various enterprises for 28 years. Based on a variety of experiences and knowledge from various companies including Arthur Andersen, Philip Morris, Nike, Schneider Electric, and recently as CFO at Handok and COO/CFO at ROKIT Healthcare, he will be instrumental to the growth of Genexine as a global innovative company leading the pharmaceutical and biotechnology industry.

Director Hwan Mook Yeo, a former member of the human resources team at LG Hausys, joined Genexine in 2020 as the director of management support. He administers the entire management support segment, including human resources, general affairs, and purchasing. Mr. Yeo graduated from Yonsei University with a business administration degree and completed his MBA from Duke University. During his 19-year career at the LG group, starting from 2001, Mr. Yeo supported management decision-making as a strategic partner and enabled organizational success through his overall involvement in strategic planning and human resources work. Based on his broad work experience, Mr. Yeo works diligently to create a corporate culture based on Genexine’s core values and establish an efficient organizational system that can achieve the common goals and vision shared by the members of Genexine.